Palomba, M. L., Patel, M. R., Eyre, T. A., Jurczak, W., Lewis, D. J., Gastinne, T., … Cheah, C. Y. (2022). Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study. In Blood (Vol. 140, pp. 557–560). American Society of Hematology. https://doi.org/10.1182/blood-2022-159123

Palomba, M Lia, Manish R. Patel, Toby A. Eyre, Wojciech Jurczak, David John Lewis, Thomas Gastinne, Shuo Ma, et al. “Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study.” In Blood, 140:557–60. American Society of Hematology, 2022. https://doi.org/10.1182/blood-2022-159123.

Palomba ML, Patel MR, Eyre TA, Jurczak W, Lewis DJ, Gastinne T, et al. Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study. In: Blood. American Society of Hematology; 2022. p. 557–60.

Palomba, M. Lia, et al. “Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study.” Blood, vol. 140, no. Supplement 1, American Society of Hematology, 2022, pp. 557–60. Crossref, doi:10.1182/blood-2022-159123.

Palomba ML, Patel MR, Eyre TA, Jurczak W, Lewis DJ, Gastinne T, Ma S, Cohen JB, Patel K, Brown JR, Scarfò L, Munir T, Lech-Marańda E, Hoffmann M, Ujjani CS, Fakhri B, Wang ML, Izutsu K, Nagai H, Tam CS, Seymour JF, Rhodes JM, Vose JM, McKinney M, Gerson JN, Barve MA, Kuss BJ, Koh Y, Gao W, Ruppert AS, Walgren RA, Tsai DE, Nair B, Bao K, Mato AR, Cheah CY. Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study. Blood. American Society of Hematology; 2022. p. 557–560.